Lutetium-177 DOTATATE: A Practical Review

Angela Y. Jia; Rojano Kashani; Nicholas G. Zaorsky; Daniel E. Spratt; Ana P. Kiess; Jeff M. Michalski; Jacqueline E. Zoberi; Hyun Kim; Brian C. Baumann

doi:10.1016/j.prro.2022.02.002

Lutetium-177 DOTATATE: A Practical Review

Angela Y. Jia, Rojano Kashani, Nicholas G. Zaorsky, Daniel E. Spratt, Ana P. Kiess, Jeff M. Michalski, Jacqueline E. Zoberi, Hyun Kim, Brian C. Baumann

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [¹⁷⁷Lu] Lu-DOTA-[Tyr³]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [¹⁷⁷Lu] Lu-DOTA-[Tyr³]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.

Original language	English (US)
Pages (from-to)	305-311
Number of pages	7
Journal	Practical Radiation Oncology
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.prro.2022.02.002
State	Published - Jul 1 2022

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.prro.2022.02.002

Cite this

@article{e671c44addb04621a05355bae39f81b5,

title = "Lutetium-177 DOTATATE: A Practical Review",

abstract = "Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [177Lu] Lu-DOTA-[Tyr3]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [177Lu] Lu-DOTA-[Tyr3]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.",

author = "Jia, {Angela Y.} and Rojano Kashani and Zaorsky, {Nicholas G.} and Spratt, {Daniel E.} and Kiess, {Ana P.} and Michalski, {Jeff M.} and Zoberi, {Jacqueline E.} and Hyun Kim and Baumann, {Brian C.}",

note = "Publisher Copyright: {\textcopyright} 2022 American Society for Radiation Oncology",

year = "2022",

month = jul,

day = "1",

doi = "10.1016/j.prro.2022.02.002",

language = "English (US)",

volume = "12",

pages = "305--311",

journal = "Practical Radiation Oncology",

issn = "1879-8500",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Lutetium-177 DOTATATE

T2 - A Practical Review

AU - Jia, Angela Y.

AU - Kashani, Rojano

AU - Zaorsky, Nicholas G.

AU - Spratt, Daniel E.

AU - Kiess, Ana P.

AU - Michalski, Jeff M.

AU - Zoberi, Jacqueline E.

AU - Kim, Hyun

AU - Baumann, Brian C.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [177Lu] Lu-DOTA-[Tyr3]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [177Lu] Lu-DOTA-[Tyr3]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.

AB - Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [177Lu] Lu-DOTA-[Tyr3]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [177Lu] Lu-DOTA-[Tyr3]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.

UR - http://www.scopus.com/inward/record.url?scp=85132455738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132455738&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2022.02.002

DO - 10.1016/j.prro.2022.02.002

M3 - Article

C2 - 35717045

AN - SCOPUS:85132455738

SN - 1879-8500

VL - 12

SP - 305

EP - 311

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

IS - 4

ER -

Lutetium-177 DOTATATE: A Practical Review

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this